Re: Pharmacoeconomic simulations

A clinical utility index (CUI), as described recently by Ouellet et al. Clinical Pharmacology & Therapeutics (2009); 85, 3, 277?282 as well as by others elsewhere, is amenable to being used as a pharmacoeconomic vehicle. Typically the CUI is derived in terms of patient benefit:risk, but could easily be adapted to other tangible measures of value. Jeff "Bonate, Peter" <Peter.Bonate Sent by: owner-nmusers 23-Apr-2009 10:37 To nmusers cc Subject [NMusers] Pharmacoeconomic simulations Is anyone aware of any papers or abstracts using computer-assisted trial design that incorporates a pharmacoeconomic component to the simulation? Or any pop pharmacokinetic-pharmacodynamic papers that include the same? Thanks Pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director Clinical Pharmacology and Pharmacokinetics 4545 Horizon Hill Blvd San Antonio, TX 78229 USA peter.bonate phone: 210-949-8662 fax: 210-949-8219 crackberry: 210-315-2713 "Beware of geeks bearing formulas". Written by Warren Buffet as part of Berkshire Hathaway's 2009 Annual Report to Stockholders. (image/gif attachment: 01-part)